Once-daily form of Glaxo's Requip filed with FDA

LONDON, April 13 (Reuters) - A once-daily form of GlaxoSmithKline Plc's (GSK.L) Parkinson's disease drug Requip has been filed for approved with the U.S. Food and Drug Administration.

Glaxo's partner on the project, SkyePharma Plc (SKP.L), whose technology was used to develop the extended-release formulation, said in a statement on Friday that the U.S. watchdog had accepted the filing of the application by Glaxo.

Requip is currently administered three times a day.

If approved for Parkinson's disease in the United States, SkyePharma will be entitled to a low mid-single digit percentage royalty on sales.

Requip is also sold for restless leg syndrome.

((Reporting by Ben Hirschler; email: ben.hirschler@reuters.com; Reuters Messaging: ben.hirschler.reuters.com@reuters.net; +44 20 7542 5082)) Keywords: SKYEPHARMA REQUIP/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWLB7641